Dr. Romeo Quijano, retired professor of Pharmacology and Toxicology at the College of Medicine, University of the Philippines Manila, noted some of the dangers of the experimental gene editing when applied to human vaccines. Quijano warns of, “the danger that the vaccine might actually “enhance” the pathogenicity of the virus, or make it more aggressive possibly due to antibody-dependent enhancement (ADE), as what happened with previous studies on test vaccines in animals. If that should happen in a major human trial the outcome could be disastrous. This serious adverse effect may not even be detected by a clinical trial especially in highly biased clinical trials laden with conflicts of interest involving vaccine companies.

https://journal-neo.org/2020/11/13/what-s-not-being-said-about-pfizer-coronavirus-vaccine/

This quote references the ferret experiments with SARS-CoV-1 (original SAARS outbreak 2002-2004) mRNA vaccines that were never approved. You can find other info about it or even the studies if you don't use Gulag for your search engine.

SPEZ: the ferrets also got liver damage, but this is separate from their lungs being destroyed when they encountered the virus in the wild:

https://www.cidrap.umn.edu/news-perspective/2004/12/sars-vaccine-linked-liver-damage-ferret-study

Here's another one on pathogenic priming and lung damage from MERS experimental mRNA vaccines:

Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. “Lung mononuclear infiltrates occurred in all groups after virus challenge but with increased infiltrates that contained eosinophils and increases in the eosinophil promoting IL-5 and IL-13 cytokines only in the vaccine groups. Inactivated MERS-CoV vaccine appears to carry a hypersensitive-type lung pathology risk from MERS-CoV infection that is similar to that found with inactivated SARS-CoV vaccines from SARS-CoV infection.”

https://www.ncbi.nlm.nih.gov/pubmed/27269431

Animal Models for SARS and MERS coronaviruses. “The concern that is extrapolated from the FIPV vaccine experience to human SARS-CoV vaccines is whether vaccine recipients will develop more severe disease if they are exposed to or infected with SARS-CoV after neutralizing antibody titers decline. The second concern is whether recipients of a SARSCoV vaccine would be at risk of developing pulmonary immunopathology following infection with an unrelated human coronavirus e.g. 229E, OC43, HKU1 or NL63 that usually causes mild, self limited disease. Although findings from preclinical evaluation have revealed these concerns, studies in animal models may not be able to provide data to confirm or allay these concerns.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550498

https://science.sciencemag.org/content/303/5660/944.ful